Federation Des Caisses Desjardins Du Quebec Biocryst Pharmaceuticals Inc Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Aug 30, 2024	SELL	$14.21 - $17.65 $68,208 - $84,720	-4,800 Closed	0 $0
Q2 2021 Aug 30, 2024	BUY	$9.5 - $17.24 $45,600 - $82,751	4,800 New	4,800 $75.9 Million
Q1 2021 Aug 30, 2024	SELL	$7.37 - $13.61 $45,694 - $84,382	-6,200 Reduced 44.29%	7,800 $79.3 Million
Q4 2020 Aug 30, 2024	BUY	$3.37 - $8.61 $47,180 - $120,539	14,000 New	14,000 $104 Million
Q3 2020 Aug 30, 2024	SELL	$3.43 - $5.53 $21,266 - $34,286	-6,200 Closed	0 $0
Q2 2020 Aug 30, 2024	BUY	$1.9 - $5.61 $11,780 - $34,782	6,200 New	6,200 $29.5 Million
Q2 2018 Aug 30, 2024	SELL	$4.6 - $6.52 $200,109 - $283,633	-43,502 Closed	0 $0
Q1 2018 Aug 30, 2024	SELL	$4.35 - $5.82 $65,271 - $87,329	-15,005 Reduced 25.65%	43,502 $207 Million
Q3 2017 Aug 30, 2024	BUY	$4.1 - $5.97 $100,937 - $146,975	24,619 Added 72.65%	58,507 $307 Million
Q2 2017 Aug 30, 2024	BUY	N/A	33,888	33,888 $188 Million

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

Vanguard Group Inc Valley Forge, PA

20.3M
Shares

$154 Million
0.0% of portfolio
Black Rock Inc. New York, NY

20M
Shares

$152 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

11.9M
Shares

$90.2 Million
1.36% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.09M
Shares

$69 Million
5.66% of portfolio
State Street Corp Boston, MA

8.85M
Shares

$67.3 Million
0.0% of portfolio

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account